EPO: Addressing Intermediate Generalizations in Pharma Patent Claims
Legal News

EPO: Addressing Intermediate Generalizations in Pharma Patent Claims

European Union·Wire Summary⏱️ 3 min read

At the European Patent Office (EPO), 'intermediate generalisations' are a frequent basis for 'added matter' objections, particularly in the context of pharmaceutical patent applications. This issue arises when a patent claim extracts a specific feature from a detailed worked example provided in the patent description and incorporates it into the claim without also including the other limiting elements of that example. The resulting claim then occupies an intermediate scope, being neither as broad as the general disclosure of the invention nor as narrow as the specific example from which the feature was derived, thereby potentially introducing new subject matter not directly and unambiguously disclosed in the original application.

This phenomenon carries significant legal implications for patent applicants and their attorneys, especially within the pharmaceutical industry where claim scope is paramount for commercial success and protection. An 'added matter' objection, if sustained, can lead to the refusal of a patent application or, if granted, to the revocation of the patent during opposition or invalidation proceedings. This directly undermines the legal certainty and commercial value of the patent, as it means the claimed invention was not fully supported by the original disclosure. The challenge lies in balancing the desire for broad patent protection with the strict requirement that all claimed subject matter must be directly and unambiguously derivable from the application as filed, preventing the applicant from gaining an unfair advantage by introducing new matter post-filing.

The legal context for 'added matter' objections at the EPO is primarily Article 123(2) of the European Patent Convention (EPC), which stipulates that a European patent application or patent may not be amended in such a way that it contains subject-matter which extends beyond the content of the application as filed. The EPO's Boards of Appeal have developed extensive jurisprudence interpreting this provision, with numerous decisions addressing the nuances of intermediate generalisations. The core principle is that the skilled person must be able to derive the amended subject-matter directly and unambiguously, using common general knowledge, from the application as filed. The difficulty often arises when attempting to combine features from different examples or to generalize a feature from a single example without explicit support for that generalization in the broader description.

Key parties involved are the European Patent Office (EPO), which examines patent applications and hears appeals, and patent applicants, typically pharmaceutical companies, research institutions, or individual inventors, along with their patent attorneys. The excerpt describes a common issue in EPO practice rather than a specific ruling or outcome. The 'examples' mentioned refer to the detailed descriptions of specific embodiments or experimental results often included in patent specifications.

Practitioner takeaway: Patent attorneys drafting and prosecuting pharmaceutical patent applications before the EPO must exercise extreme vigilance to avoid 'intermediate generalisations.' To mitigate the risk of 'added matter' objections under Article 123(2) EPC, practitioners should ensure that any generalization of features from specific examples is explicitly and unambiguously supported by the overall disclosure of the application as filed. This often requires careful wording in the description to provide a basis for combining features in various ways or for generalizing specific elements beyond the confines of a single example. Thorough review of the original disclosure to confirm direct and unambiguous support for all claimed subject matter is crucial to secure robust and valid patent protection.

Get Deeper AI analysis

How does this affect you?

Get an AI analysis of this article grounded in your jurisdictions, practice areas, and any policy documents you've uploaded to Wansom.

Finish Reading the Full Story and the Expert Analysis.

Get the latest legal & regulatory intelligence in European Union

Instant access to full analysis, cited statutes & expert commentary
Customize your dashboard to track what matters to your business operations

Already have an account? Log in

Wansom is AI and can make mistakes.